Transgenic overexpression of leptin rescues insulin resistance and diabetes in a mouse model of lipoatrophic diabetes

Ken Ebihara, Yoshihiro Ogawa, Hiroaki Masuzaki, Mitsuyo Shintani, Fumiko Miyanaga, Megumi Aizawa-Abe, Tatsuya Hayashi, Kiminori Hosoda, Gen Inoue, Yasunao Yoshimasa, Oksana Gavrilova, Marc L. Reitman, Kazuwa Nakao

Research output: Contribution to journalArticle

186 Citations (Scopus)

Abstract

Lipoatrophic diabetes is caused by a deficiency of adipose tissue and is characterized by severe insulin resistance, hypoleptinemia, and hyperphagia. The A-ZIP/F-1 mouse (A-ZIPTg/+) is a model of severe lipoatrophic diabetes and is insulin resistant, hypoleptinemic, hyperphagic, and shows severe hepatic steatosis. We have also produced transgenic "skinny" mice that have hepatic overexpression of leptin (LepTg/+) and no adipocyte triglyceride stores, and are hypophagic and show increased insulin sensitivity. To explore the pathophysiological and therapeutic roles of leptin in lipoatrophic diabetes, we crossed LepTg/+ and A-ZIPTg/+ mice, producing doubly transgenic mice (LepTg/+:A-ZIPTg/+) virtually lacking adipose tissue but having greatly elevated leptin levels. The LepTg/+:A-ZIPTg/+ mice were hypophagic and showed improved hepatic steatosis. Glucose and insulin tolerance tests revealed increased insulin sensitivity, comparable to LepTg/+ mice. These effects were stable over at least 6 months of age. Pair-feeding the A-ZIPTg/+ mice to the amount of food consumed by LepTg/+:A-ZIPTg/+ mice did not improve their insulin resistance, diabetes, or hepatic steatosis, demonstrating that the beneficial effects of leptin were not due to the decreased food intake. Continuous leptin administration that elevates plasma leptin concentrations to those of LepTg/+:A-ZIPTg/+ mice also effectively improved hepatic steatosis and the disorder of glucose and lipid metabolism in A-ZIP/F-1 mice. These data demonstrate that leptin can improve the insulin resistance and diabetes of a mouse model of severe lipoatrophic diabetes, suggesting that leptin may be therapeutically useful in the long-term treatment of lipoatrophic diabetes.

Original languageEnglish
Pages (from-to)1440-1448
Number of pages9
JournalDiabetes
Volume50
Issue number6
DOIs
Publication statusPublished - Jan 1 2001
Externally publishedYes

Fingerprint

Lipoatrophic Diabetes Mellitus
Leptin
Insulin Resistance
Transgenic Mice
Liver
Adipose Tissue
Glucose Metabolism Disorders
Lipid Metabolism Disorders
Insulin
Hyperphagia
Glucose Tolerance Test

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Transgenic overexpression of leptin rescues insulin resistance and diabetes in a mouse model of lipoatrophic diabetes. / Ebihara, Ken; Ogawa, Yoshihiro; Masuzaki, Hiroaki; Shintani, Mitsuyo; Miyanaga, Fumiko; Aizawa-Abe, Megumi; Hayashi, Tatsuya; Hosoda, Kiminori; Inoue, Gen; Yoshimasa, Yasunao; Gavrilova, Oksana; Reitman, Marc L.; Nakao, Kazuwa.

In: Diabetes, Vol. 50, No. 6, 01.01.2001, p. 1440-1448.

Research output: Contribution to journalArticle

Ebihara, K, Ogawa, Y, Masuzaki, H, Shintani, M, Miyanaga, F, Aizawa-Abe, M, Hayashi, T, Hosoda, K, Inoue, G, Yoshimasa, Y, Gavrilova, O, Reitman, ML & Nakao, K 2001, 'Transgenic overexpression of leptin rescues insulin resistance and diabetes in a mouse model of lipoatrophic diabetes', Diabetes, vol. 50, no. 6, pp. 1440-1448. https://doi.org/10.2337/diabetes.50.6.1440
Ebihara, Ken ; Ogawa, Yoshihiro ; Masuzaki, Hiroaki ; Shintani, Mitsuyo ; Miyanaga, Fumiko ; Aizawa-Abe, Megumi ; Hayashi, Tatsuya ; Hosoda, Kiminori ; Inoue, Gen ; Yoshimasa, Yasunao ; Gavrilova, Oksana ; Reitman, Marc L. ; Nakao, Kazuwa. / Transgenic overexpression of leptin rescues insulin resistance and diabetes in a mouse model of lipoatrophic diabetes. In: Diabetes. 2001 ; Vol. 50, No. 6. pp. 1440-1448.
@article{18bcfd5182d34843b8bffcc4f5ea6a2b,
title = "Transgenic overexpression of leptin rescues insulin resistance and diabetes in a mouse model of lipoatrophic diabetes",
abstract = "Lipoatrophic diabetes is caused by a deficiency of adipose tissue and is characterized by severe insulin resistance, hypoleptinemia, and hyperphagia. The A-ZIP/F-1 mouse (A-ZIPTg/+) is a model of severe lipoatrophic diabetes and is insulin resistant, hypoleptinemic, hyperphagic, and shows severe hepatic steatosis. We have also produced transgenic {"}skinny{"} mice that have hepatic overexpression of leptin (LepTg/+) and no adipocyte triglyceride stores, and are hypophagic and show increased insulin sensitivity. To explore the pathophysiological and therapeutic roles of leptin in lipoatrophic diabetes, we crossed LepTg/+ and A-ZIPTg/+ mice, producing doubly transgenic mice (LepTg/+:A-ZIPTg/+) virtually lacking adipose tissue but having greatly elevated leptin levels. The LepTg/+:A-ZIPTg/+ mice were hypophagic and showed improved hepatic steatosis. Glucose and insulin tolerance tests revealed increased insulin sensitivity, comparable to LepTg/+ mice. These effects were stable over at least 6 months of age. Pair-feeding the A-ZIPTg/+ mice to the amount of food consumed by LepTg/+:A-ZIPTg/+ mice did not improve their insulin resistance, diabetes, or hepatic steatosis, demonstrating that the beneficial effects of leptin were not due to the decreased food intake. Continuous leptin administration that elevates plasma leptin concentrations to those of LepTg/+:A-ZIPTg/+ mice also effectively improved hepatic steatosis and the disorder of glucose and lipid metabolism in A-ZIP/F-1 mice. These data demonstrate that leptin can improve the insulin resistance and diabetes of a mouse model of severe lipoatrophic diabetes, suggesting that leptin may be therapeutically useful in the long-term treatment of lipoatrophic diabetes.",
author = "Ken Ebihara and Yoshihiro Ogawa and Hiroaki Masuzaki and Mitsuyo Shintani and Fumiko Miyanaga and Megumi Aizawa-Abe and Tatsuya Hayashi and Kiminori Hosoda and Gen Inoue and Yasunao Yoshimasa and Oksana Gavrilova and Reitman, {Marc L.} and Kazuwa Nakao",
year = "2001",
month = "1",
day = "1",
doi = "10.2337/diabetes.50.6.1440",
language = "English",
volume = "50",
pages = "1440--1448",
journal = "Diabetes",
issn = "0012-1797",
publisher = "医学出版",
number = "6",

}

TY - JOUR

T1 - Transgenic overexpression of leptin rescues insulin resistance and diabetes in a mouse model of lipoatrophic diabetes

AU - Ebihara, Ken

AU - Ogawa, Yoshihiro

AU - Masuzaki, Hiroaki

AU - Shintani, Mitsuyo

AU - Miyanaga, Fumiko

AU - Aizawa-Abe, Megumi

AU - Hayashi, Tatsuya

AU - Hosoda, Kiminori

AU - Inoue, Gen

AU - Yoshimasa, Yasunao

AU - Gavrilova, Oksana

AU - Reitman, Marc L.

AU - Nakao, Kazuwa

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Lipoatrophic diabetes is caused by a deficiency of adipose tissue and is characterized by severe insulin resistance, hypoleptinemia, and hyperphagia. The A-ZIP/F-1 mouse (A-ZIPTg/+) is a model of severe lipoatrophic diabetes and is insulin resistant, hypoleptinemic, hyperphagic, and shows severe hepatic steatosis. We have also produced transgenic "skinny" mice that have hepatic overexpression of leptin (LepTg/+) and no adipocyte triglyceride stores, and are hypophagic and show increased insulin sensitivity. To explore the pathophysiological and therapeutic roles of leptin in lipoatrophic diabetes, we crossed LepTg/+ and A-ZIPTg/+ mice, producing doubly transgenic mice (LepTg/+:A-ZIPTg/+) virtually lacking adipose tissue but having greatly elevated leptin levels. The LepTg/+:A-ZIPTg/+ mice were hypophagic and showed improved hepatic steatosis. Glucose and insulin tolerance tests revealed increased insulin sensitivity, comparable to LepTg/+ mice. These effects were stable over at least 6 months of age. Pair-feeding the A-ZIPTg/+ mice to the amount of food consumed by LepTg/+:A-ZIPTg/+ mice did not improve their insulin resistance, diabetes, or hepatic steatosis, demonstrating that the beneficial effects of leptin were not due to the decreased food intake. Continuous leptin administration that elevates plasma leptin concentrations to those of LepTg/+:A-ZIPTg/+ mice also effectively improved hepatic steatosis and the disorder of glucose and lipid metabolism in A-ZIP/F-1 mice. These data demonstrate that leptin can improve the insulin resistance and diabetes of a mouse model of severe lipoatrophic diabetes, suggesting that leptin may be therapeutically useful in the long-term treatment of lipoatrophic diabetes.

AB - Lipoatrophic diabetes is caused by a deficiency of adipose tissue and is characterized by severe insulin resistance, hypoleptinemia, and hyperphagia. The A-ZIP/F-1 mouse (A-ZIPTg/+) is a model of severe lipoatrophic diabetes and is insulin resistant, hypoleptinemic, hyperphagic, and shows severe hepatic steatosis. We have also produced transgenic "skinny" mice that have hepatic overexpression of leptin (LepTg/+) and no adipocyte triglyceride stores, and are hypophagic and show increased insulin sensitivity. To explore the pathophysiological and therapeutic roles of leptin in lipoatrophic diabetes, we crossed LepTg/+ and A-ZIPTg/+ mice, producing doubly transgenic mice (LepTg/+:A-ZIPTg/+) virtually lacking adipose tissue but having greatly elevated leptin levels. The LepTg/+:A-ZIPTg/+ mice were hypophagic and showed improved hepatic steatosis. Glucose and insulin tolerance tests revealed increased insulin sensitivity, comparable to LepTg/+ mice. These effects were stable over at least 6 months of age. Pair-feeding the A-ZIPTg/+ mice to the amount of food consumed by LepTg/+:A-ZIPTg/+ mice did not improve their insulin resistance, diabetes, or hepatic steatosis, demonstrating that the beneficial effects of leptin were not due to the decreased food intake. Continuous leptin administration that elevates plasma leptin concentrations to those of LepTg/+:A-ZIPTg/+ mice also effectively improved hepatic steatosis and the disorder of glucose and lipid metabolism in A-ZIP/F-1 mice. These data demonstrate that leptin can improve the insulin resistance and diabetes of a mouse model of severe lipoatrophic diabetes, suggesting that leptin may be therapeutically useful in the long-term treatment of lipoatrophic diabetes.

UR - http://www.scopus.com/inward/record.url?scp=0034981838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034981838&partnerID=8YFLogxK

U2 - 10.2337/diabetes.50.6.1440

DO - 10.2337/diabetes.50.6.1440

M3 - Article

C2 - 11375346

AN - SCOPUS:0034981838

VL - 50

SP - 1440

EP - 1448

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 6

ER -